ArticleCureus2025
Spectrum of Cytogenetic Abnormalities in Adolescent and Young Adult Patients of B-Cell Acute Lymphoblastic Leukemia in a Tertiary Care Hospital in Pakistan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer Cytogenetics: Deep Roots, New Branches in the Age of Omics.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute lymphocytic leukemia (ALL) is a malignancy of infiltration of B or T precursor lymphoid cells, i.e., lymphoblasts, in bone marrow and other lymphoid organs. Detection of various cytogenetic abnormalities in ALL patients is important for the purpose of prognosis and targeted treatment. The aim of this study is to identify the type and frequency of various cytogenetic abnormalities in adolescent and young adult precursor B-cell ALL (B-ALL) patients in Pakistan and compare them with patients of a similar age group in other European and Asian countries.
methodsA total of 134 B-ALL patients (112 male, 22 female), aged 18-40 years, were included in this cross-sectional retrospective study, with data from December 1, 2014, to March 30, 2020, conducted in the Department of Clinical Hematology and Oncology at Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore, Pakistan. Bone marrow samples were received in the laboratory's cytogenetics section of patients diagnosed as B-ALL on flow cytometry for conventional karyotyping. After proper processing of samples with at least 400-bands level resolution, 20 bone marrow cells were counted and analyzed. Scoring and interpretation of cytogenetics was performed using the International System for Human Cytogenomic Nomenclature (ISCN 2020).
resultsOut of 134 B-ALL patients, 72 (54%) showed cytogenetic abnormalities, while 62 (46%) had normal karyotypes. Of all the B-ALL patients, translocation between chromosomes 9 and 22, t(9;22), was the most commonly detected abnormality (i.e., 13.4%).
conclusionCytogenetic analysis is important for risk stratification and targeted therapy in B-ALL, especially in regions with limited access to advanced molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.